Introduction
In developed countries, it is estimated that 0.2-1% of the population is affected by chronic wounds. [1] Chronic wounds have high associated morbidity and mortality, and current therapies can be costly and poorly effective. Thus, the identification and development of new therapeutic methods to assist wound healing [2] [3] [4] or improving the effectiveness of current wound healing strategies [5, 6] represent a major medical need. In particular, enhancing the efficacy of existing anti-inflammatory agents is likely to be the most rapidly translational approach.
Therapeutic development often relies heavily upon model systems. This enables high-throughput analysis of the role of growth factors, cytokines, and pharmaceutical agents. While animal models have the capacity to recapitulate the complex interactions of multiple cell types in vivo, such systems have limitations by the nature of using a nonhuman system. For wound healing, there are key physiological differences between the skin of Considerable progress has been made in the field of microfluidics to develop complex systems for modeling human skin and dermal wound healing processes. While microfluidic models have attempted to integrate multiple cell types and/or 3D culture systems, to date they have lacked some elements needed to fully represent dermal wound healing. This paper describes a cost-effective, multicellular microfluidic system that mimics the paracrine component of early inflammation close to normal wound healing.
Collagen and Matrigel are tested as materials for coating and adhesion of dermal fibroblasts and human umbilical vein endothelial cells (HUVECs).
The wound-on-chip model consists of three interconnecting channels and is able to simulate wound inflammation by adding tumor necrosis factor alpha (TNF-α) or by triculturing with macrophages. Both the approaches significantly increase IL-1β, IL-6, IL-8 in the supernatant (p < 0.05), and increases in cytokine levels are attenuated by cotreatment with an antiinflammatory agent, Dexamethasone. Incorporation of M1 and M2 macrophages cocultured with fibroblasts and HUVECs leads to a stimulation of cytokine production as well as vascular structure formation, particularly with M2 macrophages. In summary, this wound-on-chip system can be used to model the paracrine component of the early inflammatory phase of wound healing and has the potential for the screening of anti-inflammatory compounds.
www.advancedsciencenews.com www.advhealthmat. de humans and animal models and their corresponding healing mechanisms. [5] Moreover, 90% of medicines that appear safe and effective in animal studies fail in humans clinical trials. [7] Nevertheless, safety and ethical considerations make in vivo studies challenging in humans, whereas monoculture systems lack the cell-cell interactions seen in the skin. Cell culturing of two or more cell types together (coculturing) is a traditional research method used to mimic the complexity of human tissue interactions. The most common cell culture platform is 2D monolayer cell culturing in Petri dishes or flasks. [8] Multiple methods have been described for modeling wound healing in vitro. [9] Coculturing of human skin fibroblasts and human umbilical vein endothelial cells (HUVECs) has been used to mimic a monolayer of skin tissue. [10, 11] A variety of standardized assays have been performed to model proliferation, cell-cell signaling, and cell migration associated with wound repair. [12] [13] [14] Although conventional 2D in vitro models are less expensive than animal models and are reproducible, the physiological relevance of the information retrieved from 2D in vitro studies to in vivo systems is often questionable. [8] An organ-on-chip consists of a microfluidic device composed of a variety of cell types cultured in different layers that can interact with each other, in a highly controlled microenvironment, while mimicking the complex cell-cell and cell-matrix interactions. These platforms provide spatiotemporal chemical gradients and dynamic biomechanical environments for living organs, allowing the development of biomimetic tissues and organs as stand-alone models for drug discovery applications. [15, 16] Such platforms often utilize 2D microchannels, however, an ideal wound model enables the assembly of 3D cultures. Moreover, such an idealized system would facilitate easy sampling of culture media and quantitative analysis of cytokine levels. [17] A skin equivalent (SE) is defined as an in vitro skin model that can be used as an experimental model for studying processes such as cell migration or wound healing. The culture potential and viability of an SE is higher when inserted into a microfluidic chip [18] which has also been merged with a pumpless microfluidic chip for the purpose of drug testing. [19] However, in such prior systems, the SEs are not reconstructed directly in the microfluidic systems. [18] [19] [20] Thus, previous methodologies lack the native interactions that can occur in the formation of a multicell lineage skin model. Another group described a microfluidic-based culture system to model inflammation and edema, which utilized monolayers of epidermal (keratinocytes), dermal (fibroblasts), and vein endothelial cells. [21] While this system was reconstructed in the microfluidic chamber, it relies on a 2D culture approach and tumor necrosis factor alpha (TNF-α) to simulate inflammation. The most recent skin-on-chip model uses a full thickness SE (3D) to recapitulate epidermal morphogenesis and differentiation, [22] however, this system lacks integration of immune cells. Some studies have integrated immune cells in the human SE model by coculturing of human keratinocytes (HaCaT) with dendritic cells (U937) in two separate chambers. [23] However, none of the previous studies has developed a microenvironment of a multicellular system that includes dermal, vascular, and immune/inflammatory cells.
Wound healing is a complex process comprises of four overlapped stages: 1) hemostasis, 2) inflammation, 3) proliferation, and 4) remodeling. [24] Hamostasis immediately starts after the injury occurs and blood is coagulated as a result of platelets aggregation in the wound site. Inflammation phase takes place within 24 h postinjury and monocytes, major cells of the immune system, are accumulating in the wound environment to prevent infection. [25, 26] These monocytes then differentiate into inflammatory phenotype M1 macrophages to release different cytokines and stimulate migration of fibroblasts and endothelial cells (ECs) from surrounding tissues to the wound site. [27] The M1 cells can transform to anti-inflammatory phenotype M2 macrophages. [9] Subsequently, the M2 macrophages produce key cytokines, such as TNF-α, IL-1β, and IL-8, to induce fibroblast differentiation to myofibroblasts, extracellular matrix (ECM) production, and angiogenesis. [24, 28] It can be concluded that macrophages and their polarization from M1 to M2 phenotype have a key role in the inflammatory phase. Consequently, the transition of the inflammatory phase to the proliferation phase, preventing the hyperinflammatory hostile environment, and the formation of an acute wound rather than a chronic wound heavily depends on the inflammatory role of the macrophages. [27] During the proliferation phase, the wound microvascular structure is fully reconstructed. Re-epithelialization and formation of new tissue are controlled by migration and proliferation of keratinocytes in this phase. [29] Finally, during the remodeling phase, the normal and mature epithelial tissue is generated. [30] In this study, we attempted to develop a simple woundon-chip model to assess the effect of an active compounds on wound healing, more specifically the inflammation phase that play a key role in acute and chronic wounds. To this end, a microfluidic device that composed of three interconnected channels was used for coculturing different cell types that are involved in the inflammation phase of wound healing (fibroblasts, endothelial cells, and macrophages). This microfluidic device was used for angiogenic study and developing cancer model on a chip in previous studies by culturing of up to two cell types. [17, 31] However, we demonstrate an inflammatory wound microenvironment in the microfluidic platform based on the culturing of three different cell types.
The microenvironment in the microfluidic device was optimized to increase cell viability by optimizing cell seeding densities, cell seeding methods, and surface coating. Subsequently, this device was used to examine interactions between fibroblasts and endothelial cells under normal and TNF-α-induced inflammation. Additionally, the pro-versus anti-inflammatory effects of M1 and M2 macrophages were assessed. Finally, Dexamethasone that is a common antiinflammatory compound was used as a proof of concept to demonstrate and validate the feasibility of using this wound-onchip device to examine the impact of an active compounds on inflammation. We postulate that this wound-on-chip model is suitable for screening anti-inflammatory properties of drugs.
Results and Discussion

Optimizing Culture Conditions in the Wound-on-Chip Device
Quintessential to this microfluidic model was the establishment of a 3D culture system that formed microvasculature.
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Thus, cells were seeded initially upon ECMs, however, it was empirically found that delivery of cells within a matrix gave more even cell dispersal ( Figure S1 , Supporting Information). Next, different 3D matrices were compared including collagen I and Matrigel. Matrigel, a complex mixture of multiple ECM factors, emerged as a superior reagent for cell survival and the formation of capillaries. Immunostaining shows the vascular structure formation of HUVECs within the Matrigel as an ECM ( Figure S2 , Supporting Information). Cell seeding density was optimized based on monolayer formation for fibroblasts and macrophages, and vascular structure formation for HUVECs. These values were used for all subsequent experiments. In addition, the design of the original microfluidic device [17] was not conducive to even loading of cells in ECM. To increase the ease and reproducibility of loading, the chamber design was modified to include additional inlets for cell injection (Figure 1a) . Taken together, this device can represent the natural microenvironment of a skin wound during the inflammation and incorporates multiple cell types. The optimized culture conditions were systematically but empirically determined, although cell seeding densities would need to be redetermined for any alternate or additional cell types.
Dexamethasone Antagonizes TNF-α-Induced Inflammation in the Wound-on-Chip Model
This in vitro system enables the testing of multiple drug interactions in parallel, particularly in the case of anti-inflammatory agents where interactions between immune, dermal, and endothelial cells are critical. In order to mimic the inflammation in the absence of immune cells, HUVECs in Matrigel (in middle channel) were cocultured with fibroblasts (in both the lateral channels), and TNF-α (50 ng mL −1 ) was added for inducing inflammation in the wound-mimicking model. The effect of TNF-α treatment on endothelial cells junction formation was evaluated using an antibody against VE-Cadherin. Confocal analysis showed linear and localized junctions in the cells without any treatment, whereas, TNF-α treatment disrupted throughout the normally organized vascular structure (Figure 2) .
Dexamethasone is a steroid that is routinely used to relieve skin inflammation, treat diseases of inflammation, and inhibit TNF-α-induced inflammation. [21, 32, 33] To simulate the anti-inflammation process, Dexamethasone (1 × 10 −6 m) was applied to the fibroblasts layers that previously was damaged with TNF-α. As expected, treatment with Dexamethasone prevented TNF-α-induced disruption to the vascularization. Dexamethasone enhanced the vascular structure formation of HUVECs with linear endothelial cell-cell junctions, similar to the sample with no treatment, as seen by VE-Cadherin immunofluorescence ( Figure 2 ). The relative intensities of endothelial cell-cell staining in HUVECs were measured to quantify the fluorescence of junctions ( Figure S3 , Supporting Information). The intensity of control samples was considered as 100% for direct comparison. The intensity of TNF-α-treated samples was about 35.0%, whereas cotreatment with Dexamethasone increased the intensity up to 88.8%, showing the protective effect of Dexamethasone on endothelial junctions.
Inflammation is activated by the release of proinflammatory cytokines. Thus, we analyzed an array of human inflammatory cytokines by flow cytometry on the supernatants (1:2 dilution) collected from control, TNF-α and TNF-α-/ Dexamethasone-treated cells. The levels of proinflammatory markers were measured after 24 h of coculturing in the microfluidic device in a static condition. Consistent with previous studies, [21] 50 ng mL −1 TNF-α significantly increased the levels of proinflammatory cytokines and chemokine (IL-6 16.4 ± 0.01 ng mL −1 ; IL-1β 74.4 ± 5.8 pg mL −1 ; and IL-8 77.6 ± 0.3 ng mL −1 ) compared with untreated controls (IL-6 0.18 ± 0.01 ng mL −1 ; IL-1β 48.6 ± 0.5 pg mL www.advancedsciencenews.com www.advhealthmat.de levels (IL-6 1.7 ± 0.01 ng mL −1 ; IL-1β 46.2 ± 3.7 pg mL −1 ; and IL-8 27 ± 0.03 ng mL −1 ) (p < 0.05) (Figure 3) .
These results are consistent with the formation of vascular structures seen in Figure 2 , suggesting that reductions in proinflammatory cytokines and chemokine improve the ability of HUVECs to construct a vascular structure.
A practical use for a wound-on-chip system is to simulate inflammation during wound healing process. TNF-α plays a key role in various immunological disorders and inflammation in the skin, [34] and our data confirm that it promotes the induction of IL-6, and IL-8 similar to prior work. [21] TNF-α is also involved in endothelial cell-cell adhesion and cytokine production. [35] The action of Dexamethasone was consistent with its recognized anti-inflammatory role, [21] however, this agent was chiefly used as a prototypical anti-inflammatory agent to validate the wound model as a screening tool that could be used in future for novel drugs.
Simulating Inflammatory Conditions with Macrophages
Macrophages were incorporated into the system to simulate inflammation and to better mimic the inflammatory conditions that occur during normal wound healing. Macrophages are important regulators in wound healing, providing signal molecules important for healing and orchestrating the wound healing process. M0 macrophages were differentiated from peripheral blood mononuclear cells from healthy donors using human macrophage colony-stimulating factor (M-CSF). M0 macrophages were then polarized to M1 and M2 macrophages and then added to the microfluidic device consisting of fibroblasts and HUVECs to simulate an inflammatory skin model of the wound. Macrophage phenotype of M1 and M2 were morphologically confirmed by staining the cells with CD68 (Figure 4) www.advancedsciencenews.com www.advhealthmat.de confirmed the polarization of monocyte-derived macrophages to M1 and M2 macrophages (Figure 4 ). IL-6 proinflammatory cytokine and IL-8 proinflammatory chemokine secreted in presence of M1 (IL-6 3230.8 ± 22 pg mL −1 , IL-8 11299.2 ± 76.2 pg mL −1 ) and M2 (IL-6 994.3 ± 6.6 pg mL −1 , IL-8 14907.1 ± 856 pg mL −1 ) macrophages were significantly upregulated in the coculture conditions compared to controls without macrophages (IL-6 180.7 ± 12.3 pg mL −1 , IL-8 2593 ± 28 pg mL −1 ). These changes in proinflammatory cytokines and chemokine regulated by M1 and M2 macrophages correlate with our findings from TNF-α induce inflammation above ( Figure 3) . Importantly, compared to coculturing condition with M1 macrophages, presence of M2 macrophages was lead to have less proinflammatory cytokines (IL-6, 3230. (Figure 5 ), which is a potent promoter of angiogenesis. In summary, M1 macrophages produced IL-6 as a proinflammatory cytokine, whereas a higher level of IL-8 was accumulated in the presence of M2 macrophages as a proinflammatory and proangiogenic chemokine. The incorporation of immune cells into the microfluidic model represents the natural microenvironment of wound conditions.
We next examined the effectiveness of Dexamethasone on the macrophage-induced inflammation models. Similar to TNF-α-induced inflammation model, the addition of Dexamethasone (1 × 10 −6 m) to fibroblasts cocultured with M1 and M2 macrophages and HUVECs dramatically lowered the levels of IL-6 and IL-8 similar to the control levels ( Figure 5 ). These results are consistent with the fact that the expression level and accumulation of proinflammatory and also, proangiogenic cytokines must be decreased in later inflammatory phase to prevent hyperinflammation. Collectively, our data suggest that this inflammatory wound-on-chip model simulated by macrophages is a valid biological model for wound healing study and can potentially be used for screening of bioactive molecules or drugs.
Effects of M1 and M2 Macrophages on Vascularization
A key feature of our wound-on-chip model is the formation of vascular structures within the gel with 3D culture. Thus, we next investigated the effects of M1 and M2 macrophages on the ability of HUVECs to form vascular structure. Vascularity was visualized by staining for F-actin using Phalloidin conjugated Alexa Fluor 488 ( Figure 6) . As a control, cocultured fibroblasts and HUVECs in the absence of macrophages required 48 h for vascular structures (Figure 6a ). In contrast, the addition of M1 or M2 macrophages decreased the vascularization time to 24 h, with M2 macrophage samples showing the most robust vascularity (Figure 6b ). These structures were more apparent at higher magnification (Figure 6b-d) . CD31 immunofluorescence was quantified to measure the number of endothelial cells in the coculture system. In this assay, the inclusion of M2 macrophages in the wound-on-chip system increased CD31 . Consistent with an increased in CD31 expression, coculturing with M2 macrophages significantly enhanced angiogenesis (272 ± 3 endothelial cords per 500 µm 2 ) compared to no macrophages controls (40 ± 2) or coculturing with M1 (55 ± 2) (Figure 6g ). One potential mechanism for M2 macrophage stimulation of vascularity is the modulation of IL-8. Previous studies have indicated that this cytokine is proangiogenic. [36] 
Fibroblasts Differentiate into Myofibroblasts in Culture Independent of Macrophages
The differentiation of dermal fibroblasts to myofibroblasts is a phenomenon that normally accompanies wound healing. It leads to the production of the fibrous matrix associated with scar formation. [34] F-actin staining was examined, and alpha-smooth muscle actin (α-SMA) was used as a myofibroblast marker. [35] Undifferentiated fibroblasts showed a distinctive F-actin pattern that was disrupted after 24 h in culture (Figure 7a) . Next, the effect of M1 and M2 macrophages were compared with fibroblast/HUVEC cocultures lacking macrophages. After 24 h, dermal fibroblasts robustly expressed α-SMA (93.56 ± 0.3% of cells; Figure 7b ). The presence of M1 macrophages did not significantly affect the number of α-SMA positive cells at this time point (93.75 ± 0.2% and M2 macrophages to 95.2 ± 0.27%) (Figure 7b ). Previous studies reported that M2 macrophages are involved and enhance myofibroblast differentiation, [29] although comparable findings were not seen within the microfluidic system. It is possible that examination of α-SMA expression at different or earlier time points may reveal subtle differences, however with >90% transdifferentiation by 24 h the microfluidic system is one that potently features myofibroblast formation even in the absence of macrophages.
Conclusions
In this study, we cocultured dermal fibroblasts, HUVECs, and macrophages in a three-interconnected microfluidic device to construct a dermal wound-on-chip platform and study the interaction of these cell types during the wound healing. HUVECs formed a 3D vascular structure in the middle channel, whereas fibroblasts and macrophages formed a 2D monolayer in lateral channels and were easily migrated into the middle channel. Inflammation was induced using TNF-α, and the interaction with M1 and M2 macrophages were subsequently assessed. The role of Dexamethasone as a typical anti-inflammatory drug in improving endothelial cells junction and reducing cytokine responses (e.g., IL-6 and IL-8) was illuminated by this system. Our findings suggest that this microfluidic wound-on-chip model can mimic the inflammatory phase of wound microenvironment. It is possible to study other wound healing stages with this model by culturing different cell types that are involved in other phases of wound healing. The device has broader implications beyond the dermal wound, and it can be used to simulate inflammation in other organs. The wound-on-chip platform represents a major advancement in the capacity for a highthroughput screening of therapeutic agents effective in the Figure 7 . Differentiation of fibroblasts to myofibroblasts. a) F-actin staining of dermal fibroblasts at different time points (Blue: DAPI, Green: Phalloidin). Scale bars 100 µm. b) Confocal microscope images of fibroblasts differentiation to myofibroblasts during the triculturing with HUVECs and macrophages after 24 h using DAPI for nuclei staining in blue and α-SMA staining in green. Scale bars 200 µm.
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Experimental Section
Microfluidic Device Design and Fabrication: The cells were cultured within a microfluidic device that was developed previously [17] to construct an in vitro wound-on-chip model for wound healing study. The device consisted of three main channels (2 cm in length) (Figure 1a) : two lateral channels for 2D monolayer cell culture, and an inner channel for the 3D coculture. In order to model TNF-α inducing inflammation, human dermal fibroblasts were cultured in lateral channels while, HUVECs mixed with Matrigel (Corning, 354234) were cultured in the middle channel. In order to simulating inflammation by M1 and M2 macrophages, human dermal fibroblasts and macrophages were seeded, respectively, in the two lateral channels (each cell type in one channel), while the inner channel was filled with Matrigel mixed with HUVECs (Figure 1b) .
The microfluidic device was fabricated with polydimethylsiloxane (PDMS-Sylgard 184, Dow Corning) using standard soft lithography techniques. [37] Briefly, microfluidic geometries were designed with Autocad and then printed to a high-resolution (>8000 dpi) transparency plastic film. Silicon wafers (4 in. Siegert, DE) were used for mold fabrication. SU8-2100 (Microchem) was spun at 120 µm on the surface, and after the baking process, it was exposed to UV light. Development was achieved with the SU8 developer (Microchem). Hard baking was conducted at 160 °C for 2 h. PDMS was used at the 1:10 ratio (cure agent:base) and baked at 80 °C for 2 h. The chip was peeled, cut, and punched before being sealed to a coverslip (Thermo Scientific Menzel, 24 × 60 mm) by using plasma treatment (Harrick Plasma, PDC-002). [38] Accessing to each lateral channel was optimized for better cell seeding. The lateral channels were punched to have three 4 mm holes. Cells in their own medium were seeded to the lateral channels using these holes ( Figure 1a) . All devices were autoclaved in Milli-Q water for 20 min followed by a dry autoclave cycle for 20 min before coating.
Microfluidic Device Coating: All channels in the microfluidic devices were treated with collagen or fibronectin to enhance attachment of the fibroblasts, HUVECs, and macrophages to the device. [39] Collagen I (Corning Collagen I, Rat Tail, 100 mg (#354236) solution with a final concentration of 2 mg mL −1 (23 µL acetic acid + 20 mL water + 280 µL collagen) was prepared on ice and used for device coating. Fibronectin (Sigma, F2006) solution with a final concentration of 30 µg mL −1 was another ECM to coat the microfluidic devices. The prepared solution of desired ECM was injected into the microchannels and incubated at room temperature for 1 h. After incubation, the coating solution was aspirated from the microchannels. The channels were then washed with sterile Milli-Q water three times. Devices were dried at 37 °C overnight to make them ready for cell loading. All devices were kept in a sterile Petri dish.
Cell Culture and Maintenance: Human dermal fibroblasts (GM-3348) were cultured in T75 flasks (Corning) and passaged once the cells exceeded 80% confluent (passages 15-17 were used in these experiments). Every two days, the cell culture medium was replaced with Minimum Essential Medium (Gibco, 12571063) supplemented with 10% fetal bovine serum (Gibco, 16000036) and 1% penicillin (5000 U mL −1 )-streptomycin (5000 µg mL −1 ) (Gibco, 15070063). HUVECs (Lonza, CC-2935) were cultured in endothelial cell growth medium, EGMplus, supplemented with SingleQuot kit (Lonza, CC-5035) including l-glutamine 25 mL, fetal bovine serum (FBS) 10 mL, ascorbic acid 0.5 mL, recombinant human epidermal growth factor (rhEGF) 0.5 mL, hydrocortisone 0.5 mL, heparin 0.5, bovine brain extract (BBE) 1 mL, and GA-1000 0.5 mL. HUVECs between passages 4 and 5 were used in all experiments. Both fibroblasts and HUVECs were cultured under 5% CO 2 at 37 °C incubator.
Differentiation and Polarization of Monocyte-Derived Macrophages: White cell concentrates (buffy coats) were obtained from the Red Cross Blood Service in New South Wales (NSW). All samples and procedures were approved by the Royal Prince Alfred Hospital (RPA) Ethics Review Committee (X9.5/JUL17). Peripheral blood mononuclear cells were isolated from healthy donors' buffy coats (Heart Research Institute, Sydney) by Ficoll-Paque (GH-Healthcare) density gradient centrifugation and monocytes were isolated using Percoll (GH-Healthcare). 2.5 × 10 6 monocytes were maintained in a six-well plate using RPMI 1640 (ThermoFisher, 11875093) supplemented with 20% fetal bovine serum, 1% penicillin-streptomycin (5000 U mL −1 ), and 100 ng mL −1 recombinant human M-CSF (Macrophage colony-stimulating factor, MILTENYI, 130-096-489) for six days to generate macrophages (hereafter labeled as M0). Macrophages were then polarized to M1 and M2. M0 macrophages, seeded in 6-well plates (2.5 × 10 6 cells per well), were cultured in RPMI 20% FBS + 1% Penicillin (5000 U mL −1 )-Streptomycin (5000 µg mL −1 ) treated with Lipopolysaccharide (LPS) (from Escherichia coli 055:B5, InvivoGen tlrl-pb5lps) with final concentration of 100 ng mL −1 and Interferon gamma (IFN-γ) (MILTENYI, 130-096-481) with final concentration of 20 ng mL −1 for at least 24 h to be polarized to M1 macrophages. In order to have M2 macrophages, treatments with M-CSF with a final concentration of 20 ng mL −1 and Interleukin 4 (IL-4) (MILTENYI, 130-093-920) with a final concentration of 20 ng mL −1 for at least 24 h were performed.
Cell Seeding in Matrigel 3D Matrix and Cell Loading: HUVECs were detached from the T75 flask using Trypsin-EDTA 0.25%, and 2.5 × 10 6 cells were suspended in cold (4 °C) 12% Matrigel solution in DMEM/F-12 (ThermoFisher, 11320033) within an ice box to prevent gel polymerization. About 10 µL of the gel/cell solution was added immediately to the 3D channel, and the microfluidic device was kept in a sterile Petri dish. To prevent the evaporation of media, 10 mL of sterile phosphate buffered saline (PBS) was added to the Petri dish (as humidity chamber) and the chip was moved to the incubator for 45 min to allow gel polymerization. In the meantime, both fibroblasts and macrophages were collected and suspended in their own media at the final concentration of 2 × 10 6 cells and introduced to their respective channels. For the experiments without macrophages, fibroblasts were seeded in both the lateral channels. The cell culture medium for each cell type was changed on a daily basis until sample preparation for analysis.
Immunostaining: Cell culture media was removed from the microchannels, and the device was rinsed with PBS. Cells and vascular structure that formed within the microfluidic devices were fixed with 4% paraformaldehyde (PFA) for 15 min at room temperature. Permeabilization and blocking were performed for 1 h with 1% Triton-X solution containing 3% Blocking bovine serum albumin (BSA) (Thermo Scientific, 37525) in PBS. To demonstrate the endothelial cell-cell junctions staining with VE-Cadherin (1:50, rabbit, Invitrogen, PA5-19612) was carried out. Immunofluorescence staining of endothelial cell marker (CD31 antibody) (1:100, mouse, Invitrogen, MA5-13188) was performed to show the expression of this protein during the formation of vascular networks. α-SMA monoclonal antibody (1:100, mouse, Invitrogen, MA5-11547) were used as a myofibroblast marker to show the differentiation of fibroblasts to myofibroblasts during the triculturing. CD68/Macrophage marker Ab-3, mouse monoclonal antibody (1:100, ThermoScientific, MS-397-P0) was used to stain the macrophages. Anti-MHC class II antibody (1:100, rabbit, Abcam, ab180779) was used as an M1 macrophage marker. Anti-Mannose Receptor (1:100, rabbit, Abcam, ab64693) was used to show CD206 positive M2 macrophages. Goat anti-rabbit IgG (H+L) secondary antibody conjugated with Alexa Fluor 568 (1:50, Invitrogen, A-11036), goat anti-mouse IgG (H+L) secondary antibody conjugated with Alexa Fluor 568 (1:100, Invitrogen, A-11004), and goat anti-mouse IgG (H+L) highly cross-adsorbed secondary antibody conjugated Alexa Fluor Plus 488 (1:50, Invitrogen, A32723) were used as secondary antibodies to stain the cells. 4′,6-Diamidino-2-phenylindole, dihydrochloride (DAPI) was used for nuclei staining and Alexa Fluor 488 Phalloidin (1:100, Invitrogen, A12379) was used for F-actin staining of HUVECs and fibroblasts.
Microscopy: Images of the vascular network were taken with a confocal microscope (Nikon AR1 Advance). Individual images were taken and deconvoluted using Huygen Professional 17.04 software (SVI, www.advancedsciencenews.com www.advhealthmat.de the Netherlands). Z-stack images were taken by scanning every 5 µm in thickness. 2D images of monolayers have been merged via FIJI (ImageJ).
Measuring Cell Fluorescence Using ImageJ:
In order to quantify the expression of VE-Cadherin and CD31 markers, the mean fluorescent intensity per cell for at least 10 cells per condition was measured using ImageJ. The expression level of the markers derived from immunofluorescent data was quantified using ImageJ. [40] Induction of Inflammation with TNF-α: TNF-α (ThermoFisher, 10602HNAE250) solution with a final concentration of 50 ng mL −1 was added to the fibroblast layers after cell seeding, and the sample was incubated at 37 °C for 24 h. Then, the medium was collected from fibroblasts channels in order to quantify the level of proinflammatory cytokines (IL-12p70, TNF, IL-10, IL-6, IL-1β, and IL-8) expression with a flow cytometer.
Treatment of Inflammation Using Dexamethasone and Analysis of its Effect and Mechanism: Dexamethasone (Sigma, D2915) solution with final concentration of 1 × 10 −6 m was applied to the fibroblasts that were previously exposed to TNF-α for 24 h (for TNF-α-induced experiments) and also for the chips with macrophages after cell seeding. The devices treated with Dexamethasone were incubated at 37 °C for 24 h, and then the level of proinflammatory cytokine and chemokine expression was measured with a flow cytometer. The data were compared with the samples of HUVECs and dermal fibroblast coculturing without TNF-α as a control.
Flow Cytometry: Flow cytometry was used as a quantitative method in order to study the inflammation and inflammatory cytokines released during the cell triculturing. The medium was collected from fibroblasts and macrophages channels and stored at −80 °C until the analysis. Human inflammatory cytokines kit (BD Biosciences, 551811) was used to measure the inflammatory cytokines (IL-12p70, TNF, IL-10, IL-6, IL-1β, and IL-8). The method was based on the serial dilution of the standards or samples mixing with six different human inflammatory cytokine capture beads and detection reagent. All samples were then analyzed with flow cytometer. The data from this experiment was quantified using FCAP Array software.
Statistical Analysis: Statistical comparisons of analyzed values were obtained using the GraphPad Prism software (V. 7.02). All results reported here were as mean ± standard deviation (n = 3 for each). p-values were determined using one-way analysis of variance (ANOVA) with Tukey's post hoc for multiple comparisons. Statistical significance was accepted at p < 0.05 [indicated in the figures as * (p < 0.05)].
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